EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation

ENRICH-AF is a prospective, randomized, open-label blinded end-point (PROBE), multicenter international trial. The primary goal of the study is to investigate the efficacy of edoxaban (60/30mg daily) compared to non-anticoagulant medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) for stroke prevention in high-risk patients with atrial fibrillation and previous intracranial hemorrhage.